| Country or region | Year(s) of assessment | % of cancer patients receiving radiotherapy | Data sources | Cases analysed | Reference |
| Netherlands | 1990 | 47% | α | 27,700 | Van Daal and Bos, 1997 [10] |
| USA | 1991 | 50% - 60% | σ | * | ISCRO, 1991 [9] |
| Sweden | 1992 | 32% | α | 2988 | SBU, 1996 [11] |
| Netherlands | 1997 | 48% | β | 31,447† | Slotman and Leer, 2003 [14] |
| Netherlands | 1997 | 47% | δ | 28,892 | Slotman and Leer, 2003 [14] |
| Australia | 1998 | 37% | β | 9940 | Barton, 2000 [12] |
| Spain | 2000 | 38% | α | 44,505† | Esco et al., 2003 [13] |
| Sweden | 2001 | 47% | α | 4171 | SBU, 2003 [15] |
| Austria | 2002 | 42% | α | 3783 | Ramona et al., 2004 [16] |
| Africa | 2002 | 55% | γ | * | Barton et al., 2006 [28] |
| Brazil | 2002-2004 | 43% | δ | 50,600 | Gomes Junior and Almeida, 2009 [29] |
| Italy | 2003 | 41% | α | 10,560 | Pagano et al., 2007 [17] |
| Australia | 2003 | 52% | φ | * | Delaney et al., 2005 [20] |
| Scotland | 2003 | 46% | β | 11,932 | Erridge et al., 2007 [18] |
| Scotland | 2005 | 44% - 48% | φ | * | Erridge et al., 2007 [18] |
| Japan | 2007 | 26% | β | 218,000 | Teshima et al., 2010 [19] |
| England | 2007-2009 | 41% | φ | * | Round et al., 2013 [21] |